Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bowser

Showing results (101-110 of 147) with videos related to

Pageof 15
Sort By:
Clinical Biochemistry|May 13, 2010
Identification of a complex between fibronectin and aggrecan G3 domain in synovial fluid of patients with painful meniscal pathologyGaetano J Scuderi, Naruewan Woolf, Kaitlyn Dent, et al.
JAMA Neurology|October 17, 2022
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A ReviewJeremy M Shefner, Richard Bedlack, Jinsy A Andrews, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2007
Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosisArie Gruzman, William L Wood, Evgenia Alpert, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|November 26, 2011
Biochemical alterations associated with ALSKay A Lawton, Merit E Cudkowicz, Meredith V Brown, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 2, 2014
Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimicsKay A Lawton, Meredith V Brown, Danny Alexander, et al.
Neurology. Clinical Practice|September 3, 2021
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study DesignJames Berry, Benjamin Brooks, Angela Genge, et al.
Annals of Clinical and Translational Neurology|August 30, 2023
Proteomics and mathematical modeling of longitudinal CSF differentiates fast versus slow ALS progressionLucas Vu, Krystine Garcia-Mansfield, Antonio Pompeiano, et al.
Journal of Neuroscience Research|March 3, 2004
Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's diseaseXiongwei Zhu, Andrew McShea, Peggy L R Harris, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 18, 2013
Mechanisms, models and biomarkers in amyotrophic lateral sclerosisMartin R Turner, Robert Bowser, Lucie Bruijn, et al.
Elife|June 11, 2019
Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALSErnesto Manzo, Ileana Lorenzini, Dianne Barrameda, et al.
Pageof 15

Showing results (101-110 of 147) with videos related to

Sort By:
Pageof 15
Clinical Biochemistry|May 13, 2010
Identification of a complex between fibronectin and aggrecan G3 domain in synovial fluid of patients with painful meniscal pathologyGaetano J Scuderi, Naruewan Woolf, Kaitlyn Dent, et al.
JAMA Neurology|October 17, 2022
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A ReviewJeremy M Shefner, Richard Bedlack, Jinsy A Andrews, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2007
Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosisArie Gruzman, William L Wood, Evgenia Alpert, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|November 26, 2011
Biochemical alterations associated with ALSKay A Lawton, Merit E Cudkowicz, Meredith V Brown, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 2, 2014
Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimicsKay A Lawton, Meredith V Brown, Danny Alexander, et al.
Neurology. Clinical Practice|September 3, 2021
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study DesignJames Berry, Benjamin Brooks, Angela Genge, et al.
Annals of Clinical and Translational Neurology|August 30, 2023
Proteomics and mathematical modeling of longitudinal CSF differentiates fast versus slow ALS progressionLucas Vu, Krystine Garcia-Mansfield, Antonio Pompeiano, et al.
Journal of Neuroscience Research|March 3, 2004
Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's diseaseXiongwei Zhu, Andrew McShea, Peggy L R Harris, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 18, 2013
Mechanisms, models and biomarkers in amyotrophic lateral sclerosisMartin R Turner, Robert Bowser, Lucie Bruijn, et al.
Elife|June 11, 2019
Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALSErnesto Manzo, Ileana Lorenzini, Dianne Barrameda, et al.
Pageof 15